UNSPSC 51282304: Erythromycin

This classification denotes a macrolide antibiotic with the molecular formula C37H67NO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63937KV33D, chemically known as sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin but generally known as erythromycin, which bears US NIH Compound Identifier 3255. European Medicines Agency schedules Erythromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06605MIG.

UNSPSC 51282304 Erythromycin is a Commodity code that represents pharmaceutical products purchased through state and local supply chains, though the recent opportunities block shows little activity specifically tagged to erythromycin itself. State and local governments buy pharmaceutical products under this code through piggyback contracts, cooperative purchasing agreements, and direct buys — typically via health departments, county health systems, and public health agencies managing emergency preparedness, community health programs, and disease prevention. The work involves procuring branded and generic medications in bulk quantities, often with multi-year contract terms and quarterly or on-demand delivery schedules to central warehouses or designated health facilities. Issuing bodies include state departments of public health, county health departments, and special-purpose public health districts.

Recent activity shows limited direct opportunities under the erythromycin code itself. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026, but the products were Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg — not erythromycin — under Invitation for Bid process 26482DPHPREPDB53392. Seminole County, Florida posted an IFB (60459723LAS) in June 2026 for Naloxone and Safe Drug Deactivation Systems, again outside the erythromycin scope. The code shows activity concentrated in Florida and Illinois health departments and county systems, though the tagged opportunities diverge substantially from the code's nominal scope. Vendors pursuing pharmaceutical supply contracts in this space should expect cooperative purchasing vehicles, E-Verify compliance requirements, and multi-year terms with renewal options, but should verify that erythromycin — or generic equivalents — aligns with actual state and local purchasing patterns before investing heavily in this code.